NeoGenomics stock consolidates near $13.24 support after weekly decline

NeoGenomics stock consolidates near $13.24 support after weekly decline
NeoGenomics up 0.76% today at $13.24

NeoGenomics announced that its webinar on liquid biopsy testing for diagnosis and treatment selection is now available to stream on demand.

Highlights

  • NeoGenomics trades at $13.24, pressured below short-term averages but maintains a long-term uptrend above its 200-day moving average.
  • Technical indicators show oversold conditions and seller dominance in the short term, yet momentum signals remain robust and longer-term buy signals prevail.
  • NEO is forecast to consolidate between $12.60 and $13.90 next week, with a high probability for price recovery toward $14.40 if resistance breaks.

The company stated the session covers clinical applications, real-world case studies and implementation strategies. Viewers can watch the full recording online.

Intermediate gains hold as short-term resistance caps upside

NeoGenomics (NEO) is trading at $13.24, sitting below the SMA-20 ($14.40) but above the SMA-50 ($12.08) and SMA-200 ($10.72). This positions NEO under short-term and medium-term selling pressure, while longer-term uptrends remain intact. The Ichimoku Kijun at $13.07 acts as immediate support. Near-term support is at $13.07 (Kijun), with key support at $12.08 (SMA-50). Near-term resistance lies at $14.40 (SMA-20), and key resistance stands at $14.21 (SMA-10 EMA cluster).

Oversold momentum signals clash with ongoing price weakness

MACD on D1 indicates strong bullish momentum, supported by a robust ADX value, although RSI (45.73), Stoch RSI (0.00), CCI (–199.79), and BBP (0.02) all flag oversold conditions, pointing to short-term seller dominance. The Awesome Oscillator remains neutral, not confirming the prevailing trend. Over the past week, NEO has fallen $0.65 (5.40%) from last week's close at $13.89, now trading near the very bottom of its weekly range. Weekly volatility stands at 11.75%. This price action reflects a steady decline from the high, with momentum indicators on D1 diverging as medium-term sells outweigh long-term buy signals.

Upside bias prevails as oversold levels limit downside risk

Looking ahead, the expected price range for NEO over the next week is $12.60 to $13.90, adjusted for recent volatility and anchored within the current price band. Given that RSI-W1, ADX-W1, MACD-W1, and the SMA-50-W1 all issue Buy signals, the probability of a price increase is very high (more than 80%), making a further decline much less likely. Baseline scenario: NEO consolidates within $12.60–$13.90 as oversold conditions attract buyers. Bullish scenario: A move above $13.90 could target the $14.40 resistance area. Bearish scenario: If $13.07 breaks, watch for extended downside toward $12.08. This range keeps NEO well clear of its 52-week low ($4.72) and within reach of the yearly high ($15.57).

Previously it was reported that NeoGenomics maintained a bullish technical backdrop despite short-term selling pressures and mixed momentum indicators. This article expands on that outlook with updated analysis, highlighting the importance of monitoring for a decisive move that could signal either a renewed uptrend or deeper consolidation in the current environment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.